Abstract:Objective: To explore the therapeutic effect and mechanism of triptolide on membranous neph ropathy using passive Heymann nephritis (PHN) in rats. Methodology: Passive Heymann nephritis was induced in SD rats using rabbit antiserum against FxIA antigen. SD rats were divided into three groups, including normal controls, PHN rats with or without treatment with triptolide. PHN rats were administrated orally with triptolide (200 μg/kg per day). After the treatment with triptolid e for 7, 14, 21 and 28 days,the 24hr urine and blood were collected to examine the levels of proteinuria, serum albumin, aminotransferases, serum creatinine an d white blood cell counts. The renal tissue was processed for the examinations o f light microscopy, electron microscopy, immunefluorescene and immune electron m icroscopy. The deposition of IgG and C5b-9 along capillary wall was observed. T he distribution of nephrin and podocin as the expression of slit diaphragm prote ins was also determined. Results: (1) Urinary protein: Triptolide could significantly reduce proteinuria in rats with passive Heymann nephritis. This effect could be seen at day 7 after the tre atment and got more prominent at day 14 and persistent on day 21 and 28. At the same time, the plasma albumin was also significantly increased(P<0.01). ( 2) Subepithelial immune deposits: The examination of electron microscopy showed that the subepithelial immune deposits, spikes formation and basement membrane proliferation were improved after treatment with triptolide. The subepithelial i mmune deposits decreased and the reaction of basement membrane was also ameliora ted. However, the subepithelial immune deposits still existed although the urina ry protein decreased significantly. (3) Glomerular deposition of IgG and C5b-9: The immunefluorescene observation indicated that the deposition of IgG and C5b -9 decreased after treatment with triptolide. Compared with Heymann nephritis, the intensity of fluorescene decreased, especially after treatment with triptoli de for 7 days. (4) Injuries on podocytes: After treatment with triptolide for 7, 14, 21 and 24 days, the injuries on foot process of podocyte were recovered com pared with that in Heymann nephritis. The effacement of the podocyte foot proces ses was improved. The mean width of foot processes was decreased. Most foot proc esses was restored to normal shape after treatment with triptolide for 28 days. (5) Change of slit diaphragm related protein: After treatment with triptolide fo r 7 days, the expression of nephrin and podocin was significantly increased comp ared with that in Heymann nephritis. The abnormal distribution of nephrin and po docin started to be corrected. After treatment with triptolide for 21 days, the expression of nephrin and podocin was mostly restored to normal continuous linea r expression. The immune electron microscopy confirmed the therapeutic effect of triptolide on the restoration of nephrin expression. Conclusion: Triptolide could effectively reduce proteinuria and alleviate the glomerular imm une injuries, and also remarkably improve the podocyte lesion and help to restor e the normal structure of slit diaphragm. In addition to its immunosuppression a nd anti-inflammation activity, the therapeutic effect of triptolide might be du e to its direct activity on the treatment with podocyte injuries.

Therapeutic effect of triptolide on podocyte injury in nephrosis rats induced by puromycin aminonucleoside

Triptolid ameliorate podocyte injury induced by puro mycin aminonucleoside in vitro

Tripterygium Glycoside Protects Against Puromycin Amino Nucleoside-Induced Podocyte Injury By Upregulating Autophagy

Therapeutic effect of triptolide on podocyte injury in passive Heymann nephritis

Triptolide protects podocytes via autophagy in immunoglobulin A nephropathy.

Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro.

Tripterygium glycoside protects diabetic kidney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating β-arrestin-1.

Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro.

Triptolide Markedly Attenuates Albuminuria and Podocyte Injury in an Animal Model of Diabetic Nephropathy.

Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models.

Investigation of Inhibition of Thrombospondin-1 ( TSP-1 ) Expression by Puerarin in Kidney of Diabetic

Calcineurin Inhibitors Ameliorate PAN‐induced Podocyte Injury Through the NFAT–Angptl4 Pathway

Triptolide Protects Podocytes from Injury

Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway

Protective effects of Panax notoginseng saponins on PME-Induced nephrotoxicity in mice.

Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat

Triptolide attenuates proteinuria and podocyte apoptosis via inhibition of NF-κB/ GADD45B

Establishment of a podocyte cell injury model induced by puromycin aminonucleoside

[Effect of Triptolide on the Expression of RANTES in the Renal Tissue of Diabetic Nephropathy Rats].

Triptolide Protects Podocytes from TGF-β-induced Injury by Preventing Mir-30 Downregulation.

Inhibition of Microrna-130B Alleviated Podocyte Injury Induced by Puromycin Aminonucleoside in Vitro.